Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.68 |
| ▸ | NPY1R | P25929 | 10/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.68 |
| ▸ | NPY2R | P49146 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392718 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7248017 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3993177 | 1.00 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29574373 | 0.98 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30334190 | 0.97 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31606458 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31314376 | 0.95 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30866929 | 0.95 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29969342 | 0.95 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20630936 | 0.94 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | AMGEN INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | AMGEN INC. (US) | 2025-03-25 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| US-12097237-B2 | Small molecule Ras inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-24 | — | — | US | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| CN-107922458-A | Composition containing amino acid and cyclic dipeptide | 三得利控股株式会社 | 2018-04-17 | — | — | CN | claimed |
| CN-106459151-A | Cyclic dipeptide-containing composition | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-105407907-A | Uric acid level lowering agent | SUNTORY HOLDINGS LTD | 2016-03-16 | — | — | CN | claimed |
| US-6464959-B1 | PROTECTIVE COLLOID STABILIZER. | AEROPHARM TECHNOLOGY INCORPORATED | 2002-10-15 | — | — | US | claimed |
| WO-2002066011-A1 | MODULATED RELEASE PARTICLES FOR AEROSOL DELIVERY | AEROPHARM TECHNOLOGY, INC. (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002066008-A1 | MODULATED RELEASE PARTICLES FOR AEROSOL DELIVERY | AEROPHARM TECHNOLOGY, INC. (US) | 2002-08-29 | — | — | WO | claimed |
| US-20020110525-A1 | Modulated release particles for lung delivery | KOS LIFE SCIENCES, INC. | 2002-08-15 | — | — | US | claimed |
| US-20020110528-A1 | Modulated release particles for aerosol delivery | KOS LIFE SCIENCES, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002005785-A1 | MODULATED RELEASE THERAPEUTIC AEROSOLS | AEROPHARM TECHNOLOGY INCORPORATED (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001082980-A1 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001082868-A2 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001082873-A2 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001060420-A1 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-08-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020110528-A1 | Modulated release particles for aerosol delivery | MSN, ADRM1, SERPINA6 | NPY4R 3399/4885NPY1R 3070/4885NPY5R 2079/4885 |
| US-12097237-B2 | Small molecule Ras inhibitors | KRAS, HRAS, NRAS | NPY4R 4878/4885NPY1R 4859/4885NPY5R 4862/4885 |
| US-20250367115-A1 | Excipients To Reduce the Viscosity of Antibody Formulations and Formulation Compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY5R 1534/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | NPY4R 1324/4885NPY1R 625/4885NPY5R 652/4885 |
| US-12257343-B2 | Excipients to reduce the viscosity of antibody formulations and formulation compositions | ARGLU1, ARG1, FCGRT | NPY4R 1403/4885NPY1R 1084/4885NPY5R 1534/4885 |
| US-20020110525-A1 | Modulated release particles for lung delivery | MUC1, CD44, CHMP4B | NPY4R 3130/4885NPY1R 2912/4885NPY5R 2188/4885 |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | NPY4R 708/4885NPY1R 438/4885NPY5R 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.